Statements (55)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:pharmaceuticals
|
gptkbp:class |
dopamine agonist
|
gptkbp:clinical_trial |
Phase III trials
|
gptkbp:clinical_use |
symptomatic treatment
improving quality of life long-term management |
gptkbp:contraindication |
severe liver impairment
concurrent use of certain medications hypersensitivity to rotigotine |
gptkbp:dosage_form |
gptkb:patches
|
gptkbp:drug_interactions |
antidepressants
antipsychotics antiemetics other dopamine agonists |
gptkbp:effective_date |
gptkb:2007
|
gptkbp:financial_support |
avoid alcohol
do not stop abruptly monitor for unusual urges report any skin reactions |
gptkbp:form |
gptkb:patches
|
https://www.w3.org/2000/01/rdf-schema#label |
Neupro
|
gptkbp:ingredients |
rotigotine
|
gptkbp:manufacturer |
gptkb:UCB_S._A.
|
gptkbp:marketed_as |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
gptkbp:mechanism_of_action |
stimulates dopamine receptors
|
gptkbp:packaging |
single-use patches
|
gptkbp:requires |
prescription only
|
gptkbp:research_focus |
Parkinson's disease treatment
restless legs syndrome treatment dopamine receptor activity |
gptkbp:route_of_administration |
transdermal
|
gptkbp:side_effect |
dizziness
headache nausea vomiting insomnia skin reactions somnolence |
gptkbp:storage |
room temperature
protected from light |
gptkbp:strength |
10 mg/24 hours
2 mg/24 hours 4 mg/24 hours 6 mg/24 hours 8 mg/24 hours 12 mg/24 hours 16 mg/24 hours 24 mg/24 hours |
gptkbp:used_for |
gptkb:neurodegenerative_diseases
gptkb:restless_legs_syndrome |
gptkbp:bfsParent |
gptkb:UCB_S._A.
|
gptkbp:bfsLayer |
6
|